

# Shanshan Pei

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2212191/publications.pdf>

Version: 2024-02-01

30  
papers

3,870  
citations

471509

17  
h-index

477307

29  
g-index

31  
all docs

31  
docs citations

31  
times ranked

5296  
citing authors

#	ARTICLE	IF	CITATIONS
1	BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells. <i>Cell Stem Cell</i> , 2013, 12, 329-341.	11.1	1,004
2	Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. <i>Nature Medicine</i> , 2018, 24, 1859-1866.	30.7	496
3	Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche. <i>Cell Stem Cell</i> , 2016, 19, 23-37.	11.1	397
4	Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. <i>Cancer Cell</i> , 2018, 34, 724-740.e4.	16.8	390
5	Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2020, 10, 536-551.	9.4	252
6	AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. <i>Cell Stem Cell</i> , 2018, 23, 86-100.e6.	11.1	189
7	The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. <i>Nature</i> , 2014, 511, 90-93.	27.8	168
8	Targeting Aberrant Glutathione Metabolism to Eradicate Human Acute Myelogenous Leukemia Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 33542-33558.	3.4	163
9	Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. <i>Nature Cancer</i> , 2020, 1, 1176-1187.	13.2	137
10	Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells. <i>Cell Stem Cell</i> , 2020, 27, 748-764.e4.	11.1	130
11	Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. <i>Blood</i> , 2019, 134, 389-394.	1.4	108
12	Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 5565-5573.	5.2	91
13	The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells. <i>Cell Reports</i> , 2019, 27, 238-254.e6.	6.4	65
14	The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. <i>Blood</i> , 2022, 139, 584-596.	1.4	51
15	Melampomagnolide B: A new antileukemic sesquiterpene. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 1515-1519.	3.0	50
16	SomVarIUS: somatic variant identification from unpaired tissue samples. <i>Bioinformatics</i> , 2016, 32, 808-813.	4.1	44
17	Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. <i>Journal of Biological Chemistry</i> , 2016, 291, 21984-22000.	3.4	30
18	Low ferroportin expression in AML is correlated with good risk cytogenetics, improved outcomes and increased sensitivity to chemotherapy. <i>Leukemia Research</i> , 2019, 80, 1-10.	0.8	18

#	ARTICLE	IF	CITATIONS
19	Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1. <i>Haematologica</i> , 2017, 102, 1054-1065.	3.5	16
20	Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells. <i>Cell Cycle</i> , 2018, 17, 985-996.	2.6	15
21	How close are we to targeting the leukemia stem cell?. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 415-418.	1.7	14
22	The Hepatic Microenvironment Uniquely Protects Leukemia Cells through Induction of Growth and Survival Pathways Mediated by LIPG. <i>Cancer Discovery</i> , 2021, 11, 500-519.	9.4	13
23	Regulation of Mitochondrial Morphology Is Important for Leukemia Stem Cell Function. <i>Blood</i> , 2015, 126, 842-842.	1.4	7
24	Requirement for CRIF1 in RNA interference and Dicer-2 stability. <i>RNA Biology</i> , 2014, 11, 1171-1179.	3.1	6
25	The Intriguing Clinical Success of BCL-2 Inhibition in Acute Myeloid Leukemia. <i>Annual Review of Cancer Biology</i> , 2021, 5, 277-289.	4.5	3
26	Bcl-2 Inhibitor ABT-263 Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells. <i>Blood</i> , 2012, 120, 206-206.	1.4	3
27	Cellular Iron Status Is Associated with Better Survival and Increased Chemotherapy Sensitivity in AML. <i>Blood</i> , 2015, 126, 4975-4975.	1.4	2
28	Mitochondrial Fission 1 Regulates GSK3 and AMPK Signaling to Sustain Leukemia Stem Cell Function in Acute Myelogenous Leukemia. <i>Blood</i> , 2016, 128, 1703-1703.	1.4	1
29	The Role of NADPH Oxidase 2 in Normal and Malignant Hematopoiesis. <i>Blood</i> , 2016, 128, 1079-1079.	1.4	0
30	Lysosomal Acid Lipase a (LIPA) Modulates Leukemia Stem Cell (LSC) Response to Venetoclax/TKI Combination Therapy in Blast Phase Chronic Myeloid Leukemia. <i>Blood</i> , 2021, 138, 630-630.	1.4	0